hyperpolarized Xenon gas

Phase 2Small molecule

UUniversity of North Carolina, Chapel Hill

hyperpolarized Xenon gas is one of 72 small molecule programs targeting Respiratory Disorders. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory DisordersRecruiting

Lung TransplantationActive, not recruiting

ChildrenRecruiting

ImagingRecruiting

Respiratory DisordersPreclinical

Recruiting

Lung TransplantationPreclinical

Active, not recruiting

ChildrenPhase 2

Recruiting

ImagingPreclinical

Recruiting

Competition

Competitive Landscape

58 competitors in Children

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

2 2

Ozempic

Novo Nordisk

Approved

1 3

Gleevec

Novartis

Approved

1 4

Oncaspar

SServier

Approved

2 5

Velcade

SShilpa Grover, MD, MPH

Approved

1 6

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 7

Byetta

AstraZeneca

Phase 3

1 8

Neurontin

VViatris Specialty LLC

Phase 3

2 9

Somavaratan

Novo Nordisk

Phase 3

1 10

Xyrem

Jazz Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1/2Recruiting

Children

NCT02272049

Q4 2032

PreclinicalRecruiting

Respiratory Disorders

NCT02316379

Clinical

Trials by Indication[1]

Lung Transplantation1 trial

Imaging and Understanding BOS in Lung Transplantation

Completed·—··NCT02316392·6 enrolled

Children1 trial

Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults

Recruiting·—·Phase 1/2·NCT02272049·300 enrolled

Lung Disease1 trial

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03482960·11 enrolled

CLE1 trial

Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

Completed·—··NCT03593434·20 enrolled

Respiratory Disorders1 trial

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

Recruiting·CChildren's Hospital Medical Center, Cincinnati·Preclinical·NCT02316379·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for hyperpolarized Xenon gas. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hyperpolarized Xenon gas compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hyperpolarized Xenon gas. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of North Carolina, Chapel Hill

hyperpolarized Xenon gas

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2032

Trials by Indication[1]

Lung Transplantation1 trial

Children1 trial

Lung Disease1 trial

CLE1 trial

Respiratory Disorders1 trial

References

Drug Info

Quick Facts

Related News